| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.43% |
| NAV | ₹15.65 (26 Oct 2020) |
|---|---|
| Fund Started | 27 Feb 2019 |
| Fund Size | ₹55 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 12.1% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.3% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.4% |
| Cipla Ltd. | Healthcare | Equity | 6.1% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 5.1% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 3.8% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 3.4% |
| Lupin Ltd. | Healthcare | Equity | 3.4% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 3.3% |
| Natco Pharma Ltd. | Healthcare | Equity | 2.8% |
IDBI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by IDBI Mutual Fund. This scheme was made available to investors on 27 Feb 2019. Uma Venkatraman is the Current Fund Manager of IDBI Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹55 Cr and the Latest NAV as of 26 Oct 2020 is ₹15.65.
The IDBI Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 12 months.
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.